Kinfo
Climb Bio, Inc. logo

Climb Bio, Inc.

CLYMNASDAQHealthcare·US · USD
$13.33
+0.25 (+1.91%)
Close · 2026-06-29

Price

Key statistics

Valuation
Market cap749.00M USD
Enterprise value639.88M USD
Trailing P/E-15.15
Forward P/E-11.66
PEG ratio0.43
Price / sales0.00
Price / book4.22
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-21.27%
Return on equity-30.92%
Income (TTM)
Revenue0.00 USD
Gross profit0.00 USD
EBITDA0.00 USD
Net income-52.79M USD
Diluted EPS-$0.77
Rev. growth (YoY)0.00%
Balance sheet
Total cash109.56M USD
Total debt479.00K USD
Debt / equity0.32
Current ratio27.86
Book value / share$3.10
Cash flow (TTM)
Operating cash flow-53.30M USD
Levered free cash flow-34.66M USD
Shares & price
Shares outstanding47.77M
Float40.23M
Held by institutions66.46%
Beta0.10
50-day MA$10.74
200-day MA$5.76
52-week high$13.59
52-week low$1.19
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-05-07-0.30-0.20+33.33%2026-03-05-0.21-0.26−23.81%2026-01-300.420.36−14.29%2025-12-030.270.45+66.67%
About Climb Bio, Inc.

Climb Biotherapeutics, Inc. is a company in the biotechnology industry, focusing on the development and commercialization of novel therapeutic solutions. Primarily, it plays a role in advancing treatments for conditions that lack efficient medical solutions, positioning itself at the forefront of innovation in health care. The company's research and product pipeline frequently encompasses diverse therapeutic areas, leveraging cutting-edge technology and research methodologies to target complex biological processes. Climb Biotherapeutics impacts sectors such as pharmaceuticals, medical research, and health services, contributing vital new approaches that could transform patient care standards. Within the financial markets, it holds significance as a biotech entity potentially providing new breakthroughs that may influence industry standards and economic evaluations. By aiming to tackle unmet medical needs, Climb Biotherapeutics is a key player in potentially altering disease management protocols and enhancing health outcomes, thus maintaining a critical role in both the scientific community and the financial ecosystem where health innovation is a focal point of interest.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc
Employees
28
Headquarters
Wellesley Hills, MA, United States

Frequently asked questions about Climb Bio, Inc.